UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Caladrius Biosciences is implementing good security practices.
Caladrius Biosciences (NASDAQ: CLBS) is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease. The company was founded in 1980 and was formerly known as Corniche Group Inc, Phase III Medical Inc and NeoStem, Inc.
This report shows a preliminary security rating for Caladrius Biosciences. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
Role-based access control (RBAC), also known as role-based security, is an access control method ...
Data is rapidly becoming one of the most valuable assets in the modern world. The digital giants ...
Compare Caladrius Biosciences's security performance with other companies